Phase I trial investigating DCR-PH1 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 10 Aug 2017
At a glance
- Drugs DCR PH1 (Primary)
- Indications Primary hyperoxaluria
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Dicerna Pharmaceuticals
- 10 Aug 2017 Status changed from recruiting to discontinued according to a Dicerna Pharmaceuticals media release.
- 26 Sep 2016 According to a Dicerna Pharmaceuticals media release, data from this study were presented at the 17th Congress of the International Pediatric Nephrology Association.
- 21 Dec 2015 According to a Dicerna Pharmaceuticals media release, results from this trial are expected to be available in the second half of 2016.